NeuroPace Investigation: Investor Alert from Pomerantz Law Firm Pomerantz Law Firm is launching an investigation into potential securities fraud at NeuroPace, Inc. after a disappointing study result impacted stock prices.

NeuroPace Investigation: Investor Alert from Pomerantz Law Firm #United_States #New_York #Securities_Fraud #Pomerantz_Law_Firm #NeuroPace

NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald NPCE hereremove ads Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #NeuroPace #StockMarket #Investing #CFO #FinanceNews

Investors in NeuroPace, Inc. Invited to Explore Fraud Investigation by Schall Law Firm The Schall Law Firm is investigating potential securities fraud involving investors in NeuroPace, Inc. after a significant drop in share price. Learn more.

Investors in NeuroPace, Inc. Invited to Explore Fraud Investigation by Schall Law Firm #United_States #Los_Angeles #Schall_Law_Firm #Securities_Fraud #NeuroPace

Pomerantz Law Firm Investigates NeuroPace, Inc. for Investor Claims Amidst Stock Drop Pomerantz Law Firm is probing allegations involving NeuroPace, Inc. following a significant stock price drop. Investors are urged to act.

Pomerantz Law Firm Investigates NeuroPace, Inc. for Investor Claims Amidst Stock Drop #USA #New_York #Pomerantz_LLP #NeuroPace #NPCE

Pomerantz Law Firm Investigates NeuroPace, Inc. Claims on Behalf of Investors Amid Securities Concerns Pomerantz LLP initiates an investigation into potential securities fraud claims regarding NeuroPace, Inc., following a recent study's disappointing results.

Pomerantz Law Firm Investigates NeuroPace, Inc. Claims on Behalf of Investors Amid Securities Concerns #United_States #New_York #Pomerantz_LLP #NeuroPace #NPCE

Pomerantz Law Firm Launches Investigation into NeuroPace, Inc. Investors' Claims Pomerantz LLP is examining claims from NeuroPace investors for potential securities fraud. A significant stock drop followed the company's study results announcement.

Pomerantz Law Firm Launches Investigation into NeuroPace, Inc. Investors' Claims #United_States #New_York #Pomerantz_LLP #NeuroPace #NPCE

Pomerantz Law Firm Investigates NeuroPace, Inc. Investor Claims Following Stock Price Drop Pomerantz Law Firm is looking into claims from investors of NeuroPace, Inc. following significant stock price declines related to recent study results.

Pomerantz Law Firm Investigates NeuroPace, Inc. Investor Claims Following Stock Price Drop #USA #New_York #Securities_Fraud #Pomerantz_LLP #NeuroPace

#NeuroPace stock falls after setback in trial for #neuromodulation system seekingalpha.com/news/4452536-neuropace-s... #NAUTILUS study, #RNS System, #BCI #NeuroTech

NeuroPace stock falls as trial for RNS System fails (NPCE:NASDAQ) NeuroPace (NASDAQ:NPCE) stock drops as the company's NAUTILUS study for RNS System misses the primary endpoint for the overall trial population. Read more here.

#NeuroPace stock falls after setback in trial for #neuromodulation system seekingalpha.com/news/4452536... #NAUTILUS study, #RNS System, #BCI #NeuroTech

NeuroPace stock sinks following clinical study results Investing.com -- Shares of NeuroPace Inc (NASDAQ:NPCE) plummeted 36.1% today after the company reported that its primary effectiveness endpoint for the NAUTILUS study did not reach statistical significance in the overall study population. The study was designed to evaluate the safety and effectiveness of the RNS System for the treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE). While the study met the 12-week post-implant primary safety endpoint, demonstrating a favorable safety profile of the RNS System, the lack of statistical significance in the primary effectiveness endpoint for the broader study population has raised concerns among investors. However, the company noted a statistically significant response in a subset of patients with lower baseline frequency of generalized tonic-clonic seizures, which represents the majority of participants. Despite the setback in the overall effectiveness endpoint, NeuroPace highlighted several positive outcomes from the study. The data showed clinically meaningful improvements in median percent seizure reduction, responder rates, and an increase in seizure-free days over the first year of treatment. These improvements continued into the second year for patients who have progressed in the study, suggesting the RNS System’s potential for personalized patient treatment through programming over time. Dr. Martha Morrell, NeuroPace’s Chief Medical Officer, expressed optimism about the results, emphasizing the statistically significant seizure reduction in a substantial patient subgroup and durable improvements across multiple secondary endpoints. CEO Joel Becker reiterated the company’s confidence in its long-term growth strategy and the potential for future indication expansion into IGE. Leerink analyst Mike Kratky called the NAUTILUS study "surprising and disappointing," but clarified that a follow-up conference call eased fears a bit. "Overall, we would have preferred cleaner, more definitively positive topline results, but management has offered some reasons to remain positive on NPCE’s path forward in drug-resistant IGE," he said. The NAUTILUS study is a prospective, multicenter, randomized, single-blind, sham-stimulation controlled study that enrolled 100 participants, with 87 undergoing implantation of the RNS Neurostimulator and Leads across 23 epilepsy centers in the US. NeuroPace received FDA Breakthrough Device Designation status in 2021 for the potential use of its RNS System to treat IGE. NeuroPace plans to submit the full dataset to the FDA and for peer-reviewed publication and will engage with the FDA to discuss regulatory pathways based on the data. These discussions may include utilizing overall median seizure reduction data across the full study population and pursuing a more targeted indication focused on patients with lower baseline seizure frequency, who may represent a majority of patients with IGE. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #NeuroPace #StockMarket #Investing #ClinicalTrials #Epilepsy

Here’s my journey through neurosurgery in 2019! #epilepsy #UofM #surgery #brain #implant #head #neuropace #good #fun #exciting #michigan

I just (re) watched “little america” as I am assigned bed rest post #tonicclonic on concrete.
Exhausted from my seizure & medicines, but happy to be home with a CT scan that says my #NeuroPace wasn’t damaged.
Short episodes, Apple TV, all true stories of beauty that came to America.

Want to Decode the Human Brain? There's a New System for ... The entire platform is a technological chimera that synch...

Want to decode the human brain? There's a new system for that, and it's pretty wild singularityhub.com/2020/09/22/want-to-decod... by @ShellyFan via @ahier; Mo-DBRS, #MoDBRS #NeuroPace

ERROR: The request could not be satisfied

Phosphene perceptions and safety of chronic visual cortex stimulation in a blind subject thejns.org/view/journals/j-neurosur... #NeuroPace, #Orion, Orion I